NXPH4 coordinates DNA repair and macrophage polarization to promote chemoresistance in colorectal cancer
This study identifies Neurexophilin-4 (NXPH4) as a critical driver of colorectal cancer chemoresistance that functions through a dual mechanism: nuclear NXPH4 stabilizes hnRNPC to enhance DNA repair and tumor cell survival, while secreted NXPH4 reprograms macrophages toward an immunosuppressive M2-like phenotype via cholesterol homeostasis disruption, collectively linking intrinsic DNA damage responses with extrinsic immunometabolic remodeling.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Colorectal cancer is a formidable adversary, often treated with powerful drugs designed to damage the DNA of rapidly dividing cells. When these drugs work, they break the genetic instructions inside the tumor, forcing the cells to self-destruct. However, many tumors eventually learn to ignore these attacks. They repair the damage faster than the drugs can inflict it, or they recruit nearby immune cells to create a protective shield, allowing the cancer to survive and grow. This ability to resist treatment, known as chemoresistance, is the primary reason why advanced cancer remains so difficult to cure. Scientists have long searched for the specific switches inside cancer cells and their surrounding environment that flip these defenses on, hoping that understanding the mechanism would reveal a way to turn them off.
A team of researchers at Fudan University Shanghai Cancer Center has uncovered a surprising dual role played by a single protein called NXPH4. This protein, which is naturally found in the body but behaves differently in cancer, acts as a master coordinator for two distinct survival strategies. Inside the cancer cell, it helps the tumor fix the broken DNA caused by chemotherapy. Outside the cell, it changes the behavior of nearby immune cells, turning them into allies that protect the tumor. By mapping out exactly how this protein operates, the researchers have identified a new potential target for overcoming drug resistance in colorectal cancer.
The study began with a broad search for molecules that appear in higher amounts when cancer becomes resistant to treatment. The researchers analyzed genetic data from patients who responded well to chemotherapy and compared it with data from those whose cancer did not respond. They filtered these results to find secreted proteins—molecules that cells release into their surroundings—which are often easier to detect in blood tests. Among the candidates, NXPH4 stood out. It was significantly more abundant in the tissues of patients whose cancer resisted treatment. To confirm this finding, the team measured NXPH4 levels in the blood of 190 patients with metastatic colorectal cancer before they started their first round of chemotherapy. The results were clear: patients with high levels of NXPH4 in their blood were much less likely to respond to the drugs and had shorter survival times. The protein showed enough accuracy in predicting who would not respond to the treatment to be considered a useful tool for doctors, though the researchers note that larger studies are needed to confirm its full clinical value.
To understand how NXPH4 works, the scientists looked at what happens inside the cancer cells. They discovered that NXPH4 does not just sit on the surface or float outside; a portion of it travels into the nucleus, the command center of the cell where DNA is stored. There, it binds to a specific partner protein called hnRNPC. This interaction is crucial because hnRNPC is responsible for keeping the instructions for a group of proteins known as MCM2-7 stable. These MCM2-7 proteins act as a repair crew for DNA. When chemotherapy drugs like oxaliplatin or 5-fluorouracil try to break the cancer's DNA, the MCM2-7 crew rushes in to fix the damage. By protecting hnRNPC from being broken down, NXPH4 ensures that this repair crew is always ready and abundant. In experiments where the researchers reduced the amount of NXPH4, the cancer cells lost their ability to repair DNA damage, making them much more sensitive to the drugs and causing them to die.
The story does not end inside the tumor cell. The researchers also found that NXPH4 is secreted into the space surrounding the tumor, where it interacts with the immune system. Specifically, it targets macrophages, a type of white blood cell that normally patrols the body for invaders. In a healthy environment, these cells can fight cancer, but in the tumor, they often switch to a protective mode. The study showed that NXPH4 forces these macrophages to change their internal metabolism, specifically how they handle cholesterol. Normally, macrophages pump excess cholesterol out of the cell, but NXPH4 blocks the pumps, causing cholesterol to build up inside. This accumulation triggers a chain reaction that turns the macrophages into a "M2" type, a version that supports tumor growth and suppresses the immune system. When these altered macrophages were placed near cancer cells in a lab dish, they made the cancer cells significantly more resistant to chemotherapy drugs.
Finally, the team traced the origin of this protein back to a genetic switch. They identified a transcription factor, a molecule that turns genes on and off, called ZNF263. This molecule binds directly to the DNA instructions for NXPH4 and activates it. When ZNF263 is present in high amounts, it drives the production of NXPH4, which in turn activates both the internal repair system and the external immune shield. The researchers demonstrated that if they blocked ZNF263, the production of NXPH4 dropped, and the cancer cells became vulnerable to treatment again.
This work reveals a complex, two-pronged strategy used by colorectal cancer to survive chemotherapy. The same protein, NXPH4, acts as a guardian inside the cell by boosting DNA repair and as a manipulator outside the cell by reprogramming immune cells to be protective. By linking the tumor's internal repair mechanisms with the external immune environment, NXPH4 creates a robust defense system. The findings suggest that targeting this protein, or the genetic switch that controls it, could potentially break this defense, making standard chemotherapy effective again. While the study provides a detailed map of this mechanism, the researchers emphasize that further work is needed to translate these discoveries into new treatments for patients.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.